Hydroxychloroquine explained: how this disease-modifying antirheumatic drug (DMARD) treats autoimmune conditions and why it’s first-line for systemic lupus erythematosus. Hydroxychloroquine (plaquenil) is an antimalarial with powerful immunomodulatory effects used in SLE, rheumatoid arthritis, and juvenile inflammatory arthritis; it lowers mortality and reduces the risk of lupus nephritis by blocking antigen processing, T-cell activation, and autoantibody formation. In this video you’ll learn the drug’s mechanisms—interference with peptide loading onto MHC molecules and inhibition of inflammatory cytokines (TNF-α, IL-1β, IFN-γ)—and how those actions translate to clinical benefits like decreased flares, organ protection, and safer pregnancy management. We break down indications, practical advantages, and the side-effect profile in clear, actionable terms: common GI upset, the critical risk of retinopathy and maculopathy requiring baseline and periodic ophthalmologic screening, skin hyperpigmentation in sun-exposed areas from melanin binding, and rare cardiomyopathy. Viewers will gain a concise understanding of when hydroxychloroquine is indicated, how it modifies immune responses at a molecular level, and which monitoring steps optimize safety. Whether you’re a clinician refreshing DMARD choices or a patient seeking to understand treatment rationale and precautions, this overview highlights the therapeutic value and real-world applications of hydroxychloroquine. Watch to see how this long-established medication continues to play a central role in autoimmune care—and consider subscribing for more clinical drug summaries and practical monitoring tips.

Please confirm you want to block this member.
You will no longer be able to:
Please allow a few minutes for this process to complete.